Currently, BeiGene Ltd ADR [ONC] is trading at $200.99, up 8.87%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ONC shares have gain 11.27% over the last week, with a monthly amount glided 9.01%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, JMP Securities started tracking the stock with Mkt Outperform rating on September 18, 2024, and set its price target to $288. Macquarie started tracking the stock assigning a Outperform rating and suggested a price target of $259 on September 12, 2023. Jefferies initiated its recommendation with a Buy and recommended $287 as its price target on August 17, 2023. Citigroup started tracking with a Buy rating for this stock on July 17, 2023, and assigned it a price target of $275. In a note dated June 30, 2023, Bernstein downgraded an Mkt Perform rating on this stock and revised its target price from $335 to $196.
This stock has fluctuated between a low of $126.97 and a high of $248.16 over the last 52 weeks. BeiGene Ltd ADR [NASDAQ: ONC] shares were valued at $200.99 at the most recent close of the market.
Analyzing the ONC fundamentals
Trailing Twelve Months sales for BeiGene Ltd ADR [NASDAQ:ONC] were 3.32B which represents 28.20% growth.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 192.44 points at the first support level, and at 183.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 208.61, and for the 2nd resistance point, it is at 216.22.
Ratios To Look Out For
To put it in perspective, the Current Ratio for BeiGene Ltd ADR [NASDAQ:ONC] is 1.93. In addition, the Quick Ratio stands at 1.72. Considering the valuation of this stock, the price to sales ratio is 5.92, the price to book ratio is 6.24.
Transactions by insiders
Recent insider trading involved Wang Xiaodong, Chair, Scientific Advisory Brd, that happened on Jan 07 ’25 when 41760.0 shares were sold. Director, XIAODONG WANG completed a deal on Jan 07 ’25 to buy 0.13 million shares. Meanwhile, Chair, Scientific Advisory Brd Wang Xiaodong sold 41760.0 shares on Dec 10 ’24.
